Generate a tailored SOP for Dr. Jesse Cedarbaum. Improve your application with a focused, well-structured draft.
Jesse M. Cedarbaum, MD, is a neurologist and clinical trialist specializing in Movement Disorders. He graduated from Yale University School of Medicine in 1978 and has worked primarily in academia and the pharmaceutical industry. Cedarbaum led the Parkinson Movement Disorders program at New York Hospital-Cornell and has held executive positions at Regeneron, Elan, Cytokinetics, and Bristol-Myers Squibb. At Biogen, he advanced three new compounds into clinical trials for Parkinson's disease and established a clinical research program for inherited ataxias. His research has focused on developing clinical outcome measures, biomarkers, and utilizing digital health technologies in clinical trials. Cedarbaum has served on various scientific boards and has authored over 100 publications, particularly in neurological and ophthalmological therapeutics. His significant contributions include the development and validation of the ALS Functional Rating Scale, which remains a key outcome measure in ALS trials today. Cedarbaum's continued research interests include pharmacology related to Parkinson's disease and other neurodegenerative conditions.
Yale University • New Haven, CT
Contributes to academic research and collaborates with School of Medicine faculty.
Regeneron Pharmaceuticals •
Led clinical trials and research initiatives for neurodegenerative diseases.
New York Hospital-Cornell •
Headed the Parkinson Movement Disorders program.
Administered via the Graduate School of Arts and Sciences (GSAS). GRE General is optional for PhD.